GLP-1 telehealth operations in California
California is the largest compounded GLP-1 market in the US by patient volume. The Medical Board of California enforces strict CPOM doctrine, and the Board of Pharmacy actively audits 503A and 503B compounding pharmacies serving California patients.
Book a free roadmap callThe California market
California is the largest compounded GLP-1 market in the US by patient volume. The Medical Board of California enforces strict CPOM doctrine, and the Board of Pharmacy actively audits 503A and 503B compounding pharmacies serving California patients.
Operating rules in California
Corporate Practice of Medicine posture: Strict. Good faith exam format: Synchronous real-time audio and video is required for initial visits prescribing controlled substances or compounded medications. Asynchronous-only GFE is not defensible for compounded GLP-1 programs. In-person follow-up: Not universally required for compounded GLP-1, but the Medical Board expects documented synchronous follow-up at clinically appropriate intervals (typically every 90 days during titration). Pharmacy licensure: 503A compounding pharmacies serving California patients must hold a current California Board of Pharmacy nonresident sterile compounding permit (if shipping injectables across state lines). 503B outsourcing facilities require separate registration. Nurse practitioner authority: Nurse practitioners require a standardized procedure with a supervising physician to prescribe compounded medications. As of 2026, NPs with 100 Practice Authority (per AB 890) have expanded autonomy but compounded GLP-1 protocols still require physician medical director review. Controlled-substance scheduling: Compounded semaglutide is not a controlled substance, but California enforces strict adverse event reporting for compounded sterile injectables. Schedule II/III controlled substances paired with GLP-1 protocols require DEA-credentialed prescribers.
Statutes and rules cited
Cal. Bus. & Prof. Code §2052 — Practice of medicine without license: California's prohibition on the unlicensed practice of medicine — the foundation for CPOM enforcement against non-physician control of clinical decisions. Cal. Bus. & Prof. Code §2400 — Corporate Practice of Medicine doctrine: Codifies California's CPOM rule prohibiting general business corporations from practicing medicine or employing physicians for clinical purposes. PC-MSO structures are the compliant alternative. Cal. Code Regs. tit. 16 §1735 et seq. — Sterile compounding regulations: California Board of Pharmacy regulations on sterile compounding by 503A pharmacies, including patient-specific prescription requirements and documentation standards relevant to compounded GLP-1. Cal. Bus. & Prof. Code §2746.51 — Nurse practitioner standardized procedures: Requires NPs operating below 100 authority to prescribe under standardized procedures co-authored with a supervising physician — relevant to NP-staffed GLP-1 programs.